Investigating the anti-tumour efficacy and on target toxicity of gene-modified T cell therapy in vivo

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/1030436

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

White blood cells from cancer patients can be modified in the laboratory to react against tumours. Although these cells can induce cancer regression when given back to the patient, these cells can often cause associated pathology. In this study we propose to fully investigate the limits of this type of therapy for mediating anti-tumour responses and potential toxicity in mouse models that closely recapitulate the human setting. These studies will lead to a more effective therapy for patients.

Funded Activity Details

Start Date: 01-01-2012

End Date: 01-01-2014

Funding Scheme: Project Grants

Funding Amount: $337,614.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Tumour Immunology

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

T cells | cancer | cancer immunology | gene therapy | tumour immunotherapy

Related Links